{"entity":{"id":"nct06590961","kind":"trial","name":"UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies","aka":[],"tldr":"A phase 1 trial of UBX-303-1 run by Ubix Therapeutics, Inc., now recruiting.","summary":"UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies is a phase 1 interventional study registered as NCT06590961 by Ubix Therapeutics, Inc., with 94 participants planned, started 2025-02-20. Conditions recorded: Relapsed/Refractory B-cell Malignancies. Interventions recorded: UBX-303061.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06590961","url":"https://clinicaltrials.gov/study/NCT06590961"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ubx-303061"],"companies":["ubix-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06590961","phase":"1","setting":"A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies","sponsor":"Ubix Therapeutics, Inc.","enrolled":94,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06590961/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ubx-303061","kind":"drug","name":"UBX-303-1","route":"/drugs/ubx-303061/"}],"company":[{"id":"ubix-therapeutics","kind":"company","name":"Ubix Therapeutics","route":"/companies/ubix-therapeutics/"}]}}